Hims & Hers Expands Into Cardiovascular Health with New Dual-Action Capabilities

Hims & Hers Health, Inc., the leading health and wellness platform, today announced a new approach for providers to personalize sexual health treatment for men. as well as supporting heart health. Through Heart Health by Hims, providers will be able to customize treatments to combine the active ingredients in clinically proven drugs to treat multiple conditions in a single pill, demonstrates Hims & Hers’ rapidly evolving pharmaceutical and technological capabilities. .It also marks the company’s first step in heart health and is part of the company’s ever-growing mission to create personalized and comprehensive health and wellness solutions. chemical.Complementing today’s launch, Hims & Hers also announced a strategic partnership with the American College of Cardiology (ACC) to support Hims & Hers’ ongoing commitment to clinical excellence. The Heart Health by Hims method uses clinical protocols based on the principles of the Atherosclerotic Cardiovascular Disease Risk Estimator (ACC). Additionally, Heart Health by Hims customers will have access to cardiovascular health educational resources and materials through CardioSmart.org, ACC’s patient engagement initiative.In addition, Hims & Hers partnered with Labcorp, a global leader in innovative and comprehensive laboratory services. Heart Health by Hims customers will soon be able to schedule heart health checks at Labcorp’s lab at a time and place that’s convenient for them. The test results will then be integrated directly into Hims & Hers’ proprietary electronic medical records, allowing providers to further personalize care as appropriate.Nearly half of the U.S. population has some form of cardiovascular disease, which is responsible for a quarter of all male deaths nationally. Engaging in preventive heart care is vitally important, yet many people are unaware of their risk factors, limiting access to high-quality, affordable, or simple care. is not seeking preventive treatment.

“Prevention is the ideal mechanism to decrease cardiovascular events and ensure optimal heart health and requires an infrastructure for screening individuals and empowering them to actively reduce risk factors like cholesterol levels before heart disease develops,”

“By integrating ACC clinical guidance, tools and resources into Hims’ protocols, there is an opportunity to identify at-risk patients and increase patient education, lifestyle modification, initiation of appropriate preventive therapy and improve medication adherence. Given Hims’ innovative approach to engaging their patient community, this collaboration provides the opportunity to assess and treat a whole new generation of patients at scale and potentially reduce their risk of a future heart attack.”

Dr. Ami Bhatt, Chief Innovation Officer for the American College of Cardiology.

The evidence-based clinical guidelines followed by the platform’s providers have been developed in collaboration with renowned physician leaders, including cardiology expert Dr. Deepak Bhatt and men’s health expert, Dr. Martin Miner.As part of the launch of Heart Health by Hims, providers will be able to customize treatments that combine ingredients found in clinically proven erectile dysfunction drugs and statins that doctors are proud of. Supply has been trusted for decades to improve sexual health and lower cholesterol respectively. Lowering cholesterol through statin therapy may reduce mortality and protect against serious adverse cardiovascular events such as heart attack and stroke. Clinical evidence also suggests that erectile dysfunction may be an independent risk factor for cardiovascular disease – with other research showing that erectile dysfunction symptoms may precede heart disease. Clinically clear pulse takes an average of two to three years.As a trusted health and wellness pioneer with more than one million people on the platform, Hims & Hers has a unique opportunity to enable access to sexual health treatment while also identifying people with high risk factors for CVD and connect them with high-quality care. preventive care. About 30% of Hims customers have one or more factors that may put them at higher risk of developing CVD in their lifetime.

“Since the beginning of our journey six years ago, we’ve had an unwavering commitment to establish Hims as a trusted destination for men’s health and wellness, and expanding access to heart health has always been a cornerstone of that vision. Hundreds of thousands of men are lost each year to cardiovascular disease, but taking simple steps like starting a statin therapy can help men begin to address those risks,”

“I wasn’t even aware of my risk factors until recently, but I owed it to my own family to take my heart health seriously. We want to reach millions of other fathers, sons, grandfathers and husbands out there who feel the same way by expanding our capabilities to address multiple health issues at once.”

Andrew Dudum, Hims & Hers Co-founder and CEO.

The Hims & Hers method offers an effective way to deal with erectile dysfunction and high cholesterol simultaneously. Studies show that simplifying regimens can significantly improve adherence, and other research has shown that patients treated with a single-pill combination therapy are more likely to better adherence to the treatment regimen.

“If heart disease can continually be the top killer of all people annually, then the traditional healthcare system has clearly fallen short. Overcoming those shortcomings starts with removing the unnecessary barriers people face when attempting to access preventive cardiovascular care,”

“Our North Star has always been to remove these barriers and find innovative ways to connect with people who often don’t seek treatment elsewhere. That’s why we’ve been the trusted destination for hundreds of thousands of men seeking solutions for their sexual health, but now we can be a place for the millions who are at risk and don’t know it.”

Dr. Patrick Carroll, Hims & Hers Chief Medical Officer.

Next Post

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing

ADARx Pharmaceuticals, Inc., a clinical-stage biotech company developing next-generation RNA-based therapies, today announced the successful conclusion of its over-subscribed Series C funding. value of 200 million dollars. The funding was led by Bain Capital Life Science and TCGX and includes new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare […]